Cargando…

Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

BACKGROUND AND PURPOSE: After the failure of first-line treatment, the clinical prognosis in head and neck cancer (HNSCC) deteriorates. Effective therapeutic strategies are limited due to the toxicity of previous treatments and the diminished tolerance of surrounding normal tissue. This study demons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ritter, M., Teudt, I. U., Meyer, J. E., Schröder, U., Kovács, G., Wollenberg, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719334/ https://www.ncbi.nlm.nih.gov/pubmed/26792072 http://dx.doi.org/10.1186/s13014-016-0583-0

Ejemplares similares

Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis
por: Huang, Jingwen, et al.
Publicado: (2016)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020)

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
por: O’Keefe, Rachel A., et al.
Publicado: (2020)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021)

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC
por: Paulsen, Finn-Ole, et al.
Publicado: (2020)

Bronchoscopic debulking for endobronchial malignancy: Predictors of recanalization and recurrence
por: Kuo, Scott Chih-Hsi, et al.
Publicado: (2015)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
por: Akmansu, Muge, et al.
Publicado: (2010)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

Recurrent female adnexal tumor of probable Wolffian origin treated with debulking surgery, imatinib and paclitaxel/carboplatin combination chemotherapy: A case report
por: Wakayama, Akihiko, et al.
Publicado: (2017)

Anesthetic management for bronchoscopy and debulking of obstructing intratracheal tumor
por: Uma, B., et al.
Publicado: (2015)

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
por: Niehr, Franziska, et al.
Publicado: (2015)

Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin
por: Ueda, Yutaka, et al.
Publicado: (2010)

Correction: Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Chauffert, Bruno, et al.
Publicado: (2023)

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC
por: Yao, Yanli, et al.
Publicado: (2022)

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
por: Sasaki, Yasutsuna, et al.
Publicado: (2014)

Inhibition of GSK3α/β impairs the progression of HNSCC
por: Schulz, Lisa, et al.
Publicado: (2018)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2021)

Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition
por: Lin, Yu-Wei, et al.
Publicado: (2017)

Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
por: Klöss, Stephan, et al.
Publicado: (2015)

Robot-assisted laparoscopic debulking surgery for recurrent adult granulosa cell tumors
por: Groeneweg, Jolijn W., et al.
Publicado: (2021)

Salvage debulking surgery and hyperthermic intrathoracic chemotherapy for massive recurrent mesothelioma in the mediastinum
por: Poon, Shi Sum, et al.
Publicado: (2022)

Platelet Induced Functional Alteration of CD4(+) and CD8(+) T Cells in HNSCC
por: Polasky, Christina, et al.
Publicado: (2020)

ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines
por: Ayoub, C, et al.
Publicado: (2010)

Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
por: Klaassen, U., et al.
Publicado: (1996)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
por: Blinman, Prunella, et al.
Publicado: (2013)

EVI1 as a Marker for Lymph Node Metastasis in HNSCC
por: Idel, Christian, et al.
Publicado: (2020)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Debulking mastectomy with electrochemotherapy: a case report of no surgery approach to recurrent breast cancer
por: Esposito, Emanuela, et al.
Publicado: (2021)

TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC
por: Klapper, Luise, et al.
Publicado: (2022)

Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC
por: Ingruber, Julia, et al.
Publicado: (2022)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
por: Busch, Chia-Jung, et al.
Publicado: (2016)

lncRNA Expression after Irradiation and Chemoexposure of HNSCC Cell Lines
por: Guglas, Kacper, et al.
Publicado: (2018)

NR2F6 as a Prognostic Biomarker in HNSCC
por: Klapper, Luise, et al.
Publicado: (2020)

Quinary debulking for epithelial ovarian cancer
por: Edwards, James M., et al.
Publicado: (2012)

NOTCH1 Intracellular Domain and the Tumor Microenvironment as Prognostic Markers in HNSCC
por: Schmidl, Benedikt, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4hjtdbr056qhcmqch4qbbc9vlg